pocketful logo light
pocketful logo light
Lupin Ltd logo

Lupin Ltd

NSE: LUPIN BSE: 500257

₹2272.90

(0.38%)

Mon, 15 Jun 2026, 07:42 am

mtf coin illustrationMTF 5x

Lupin Share Price Live Chart

1 Day

(0.38%)

No Result Found

Summary

  • Market Cap (in Cr)

    103900.02

  • Net Profit (in Cr)

    3306.26

  • P/B

    5.38

  • Sector P/E

    33.76

  • P/E

    28.20

  • EV/EBITDA

    17.31

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    21

  • ROCE

    20.88

  • Debt/Equity

    0.27

  • EPS (TTM)

    126.13

  • Dividend Yield

    0.79

  • Book Value

    490.98

  • Interest Cover

    14.62

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters46.8646.8946.9046.9046.92
FII21.7121.4920.4921.2521.46
DII25.3225.5826.5525.5625.41
Public6.116.036.066.286.20
Government0.000.010.010.010.01

Read More

Technical Analysis

RSI

49.28

MACD

-7.33

50 DMA

2296.00

200 DMA

2145.46

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2890.902607.502437.602324.102154.202040.701757.30
Fibonacci2607.502499.242432.362324.102215.842148.962040.70
Camarilla2345.632319.662293.682324.102241.722215.742189.76

Pivots Level: Classic

R3

+566.80

2890.90

R2

+283.40

2607.50

R1

+113.50

2437.60

2324.10
2324.10
Pivot Point
LTP: 2274.20

S1

-169.90

2154.20

S2

-283.40

2040.70

S3

-566.80

1757.30

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2269.70

  • 20-EMA

    2273.75

  • 30-EMA

    2279.03

  • 50-EMA

    2280.57

  • 100-EMA

    2251.08

  • 200-EMA

    2181.78

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
07 May 2026board-meetingsAccounts, Quarterly Results, Dividend
12 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results
14 Jul 2025agm
25 Jun 2025dividendFinal Dividend - Rs. - 1225 Jul 2025
14 May 2025dividend₹12.00 Dividend /Share25 Jul 2025
09 Jul 2024agm
16 Jun 2024dividendFinal Dividend - Rs. - 816 Jul 2024
06 May 2024dividend₹8.00 Dividend /Share16 Jul 2024
04 Jul 2023agm

Read More

Peer Comparison

Lupin Ltd logo

Lupin Ltd

Cipla Ltd logo

Cipla Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Lupin Ltd About

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, Gastro- Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, USA, Mexico and Brazil with trading and other incidental and related activities extending to the global markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1983

Headquarters

CEO

M D Gupta

Employees

Contact

Website icon

Website

https://www.lupin.com/

Email icon

Email

investorservices@lupinpharma.com

Phone icon

Phone

91-22-6640 2323

Location icon

Location

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055

Read More

Lupin Ltd Company History

YearHistory
2020
  • Lupin's Pithampur facilities pass MHRA inspection.
  • Lupin launches generic arthritis relief tablet in the US.
  • Lupin receives EIR from US FDA for Florida inhalation research centre.
  • Lupin receives EIR from US FDA for Nagpur plant.
  • Lupin receives US FDA approval for generic product.
2021
  • Lupin receives US FDA approval for generic anti-fungal cream.
  • LupinLife launches ayurvedic energy supplement Be One.
  • Lupin launches Posaconazole delayed-release tablets.
  • Lupin launches generic Wilson's disease drug in the US.
  • Lupin launches generic diarrhea drug in the US.
2022
  • Lupin receives US FDA approval for Efinaconazole Topical Solution.
  • Lupin launches first reference laboratory in Kolkata.
  • Lupin receives US FDA approval for Vigabatrin for Oral Solution USP.
  • Lupin completes acquisition of brands from Anglo-French.
  • Lupin launches Merzee Capsules in the US.
2023
  • Lupin launches Softovac Liqui fibre liquid fibre product.
  • Lupin launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP in the US.
  • Lupin launches Rocuronium Bromide Injection in the US.
  • Lupin launches Diazepam Rectal Gel in the US.
  • Lupin agrees to acquire 5 drug brands from Menarini for Rs 101 crore.
2024
  • Lupin and Slurrp conclude Lupin Aptivate Achchi Bhookh Quiz.
  • Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio.
  • Lupin receives US FDA approval for Emtricitabine and Tenofovir Alafenamide Tablets.
  • Lupin acquires 3 trademarks from Boehringer Ingelheim to strengthen diabetes portfolio.
  • Lupin's Pune R&D facility awarded LEED Platinum Certification.
  • Lupin launches Bumetanide Injection USP in the United States.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell600351937.514 Oct 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy600351937.514 Oct 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy81892197713 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell81892197713 Oct 2025
STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUNDblockSell528611894.714 Jul 2025
STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUNDblockBuy528611894.714 Jul 2025
BNP PARIBAS ARBITRAGEblockSell7479561449.225 Jan 2024
SOCIETE GENERALEblockBuy7479561449.225 Jan 2024
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell22847774714 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy22847774714 Nov 2022

Read More

Lupin Ltd News

Lupin Partners With ERN to Launch Luforbec® in Spain

Lupin collaborates with Laboratorios ERN to introduce Luforbec® in Spain for treating adult asthma and COPD, expanding access to respiratory care.

08 Jun 2026

companies

Lupin gets US FDA nod for Ranluspec injection

Lupin received US FDA approval for Ranluspec, the only interchangeable biosimilar ranibizumab in vials and pre-filled syringes.

04 Jun 2026

companies

Lupin & Natco Win FDA Nod for Eribulin Mesylate

Lupin and Natco receive FDA approval for Eribulin Mesylate Injection, used to treat metastatic breast cancer and liposarcoma, with expected annual U.S. sales of $43.7 million.

03 Jun 2026

companies

Lupin CFO Eyes Large Specialty Deals With Debt Discipline

Lupin's CFO Swaminathan says the company is targeting significant specialty deals while maintaining a cautious approach to debt and risk management.

01 Jun 2026

companies

Lupin updates on Multicare deal timeline

Lupin's subsidiary Nanomi B.V. is acquiring minority shares in Multicare Pharmaceuticals Philippines. The transaction is now expected to close in July 2026.

29 May 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number